Envirotech Vehicles appoints Jason Maddox to board of directors
TARPON SPRINGS, Fla. - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company with a market capitalization of $18.21 million, has announced the unveiling of a new Drug Response Predictor (DRP®) for daratumumab, a monoclonal antibody drug used in the treatment of multiple myeloma. The presentation of this development took place at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago. According to InvestingPro data, the company’s stock has shown resilience with a significant 13.83% return over the past week, despite its overall weak financial health score of 1.74 out of 5.Want deeper insights? InvestingPro subscribers have access to over 10 additional key insights about Allarity Therapeutics, including detailed financial health metrics and valuation analysis.
The newly developed DRP® aims to identify patients with multiple myeloma who are most likely to respond to daratumumab treatment. The predictor was formulated by correlating gene expression patterns with the drug’s efficacy in triggering antibody-dependent cellular cytotoxicity, using data from cell lines of multiple myeloma and B-cell lymphoma. The analysis revealed 53 genes linked to either sensitivity or resistance to the drug, which constitute the new DRP®.
Single-cell RNA sequencing data from the KYDAR trial, which involved daratumumab in combination with other drugs, was used to validate the predictor’s ability to forecast treatment outcomes and survival rates. These results indicate the potential of the DRP® as a tool for enhancing patient selection in clinical settings.
Thomas Jensen, CEO of Allarity Therapeutics, stated that the addition of the daratumumab DRP®—the company’s first for an antibody therapy—expands the versatility of their DRP platform, which has previously been developed exclusively for small-molecule drugs. While the company maintains a healthy current ratio of 2.06, indicating strong short-term liquidity, InvestingPro analysis shows the company is quickly burning through cash, a common challenge for clinical-stage biotech firms. The company views this as a significant step towards future collaborations that aim to bring precision diagnostics to more patients.
Allarity Therapeutics focuses on the development of stenoparib, a novel PARP/tankyrase inhibitor, for advanced ovarian cancer patients, among other cancer types. Their proprietary DRP® technology is used to develop companion diagnostics that select patients expected to benefit most from their treatments.
The poster detailing the daratumumab DRP® findings will be made available on Allarity’s website in the Scientific Publications section.
This press release contains forward-looking statements regarding the potential applications of the DRP® for daratumumab and the expansion of the DRP® platform. These statements are based on current expectations and are subject to uncertainties that could affect the actual outcomes.
The information presented in this article is based on a press release statement from Allarity Therapeutics.
In other recent news, Allarity Therapeutics has reported promising results from its Phase 2 trial of stenoparib, a drug being developed for advanced ovarian cancer. The trial, presented at the Society of Gynecologic Oncology 2025 Annual Meeting, showed that some patients experienced prolonged benefits, with one achieving a complete response for over 10 months. This development is particularly significant for patients with limited treatment options, including those without BRCA mutations. Additionally, Allarity has introduced a new protocol for its ongoing clinical trial of stenoparib, focusing on refining patient selection and optimizing dosage. This is part of a broader strategy to enhance the drug’s effectiveness and support regulatory approval efforts. The company has also finalized a settlement with the U.S. Securities and Exchange Commission regarding its past FDA disclosures, which includes a $2.5 million civil penalty but does not impact its financial outlook. Furthermore, Allarity has partnered with Shareholder Intelligence Services to investigate potential illegal stock manipulation, aiming to protect shareholder interests and promote transparent trading. These developments underscore Allarity’s commitment to advancing its clinical programs and ensuring fair trading practices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.